Pay in 4 interest-free payments of $5.41 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
We caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from those made in or suggested by the forward-looking statements contained in this communication.
Continue to meet with our medical provider weekly to monitor progress and dosages
Abstract Oral delivery of peptides represents a promising alternative to invasive injectable therapies, offering improved patient adherence and convenience
Retatrutide is currently being studied in Phase 3 clinical trials and has not received FDA approval yet
4 Studies indicate that NAION occurs in up to 1 in 10,000 patients
To date, GLP-1R has been identified presynaptically on GABAergic nerve terminals (Rebosio et al., 2018) and on medium spiny neurons that express the dopamine-D1 or dopamine-D2 receptors (Zhang et al., 2020)
